Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the UK / NCT05556096
Active, not recruiting Phase 3

Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis

NCT05556096 · tracked via the Priya Life Science UK tracker
Sponsor
Alexion Pharmaceuticals, Inc
Phase
Phase 3
Started
2022-11-21
Last updated
2026-06-17

Condition(s) studied

Generalized Myasthenia Gravis

Investigational drug(s) / intervention(s)

ALXN1720Placebo

ALXN1720: Combination product consisting of syringe prefilled with ALXN1720.

Placebo: Combination product consisting of syringe prefilled with placebo.

Study summary

The purpose of this study is to evaluate the safety and efficacy of ALXN1720 for the treatment of generalized MG (gMG) in adults with autoantibodies against acetylcholine receptor (AChR).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Diagnosis of MG with generalized muscle weakness meeting the clinical criteria defined by Myasthenia Gravis Foundation of America (MGFA) Class II, III or IV * Positive serological test for autoantibodies against AChR Exclusion Criteria: * History of thymectomy, or any other thymic surgery within 12 months prior to Screening * Untreated thymic malignancy, carcinoma, or thymoma * History of Neisseria meningitidis infection * Pregnancy, breastfeeding, or intention to conceive during the course of the study

Primary outcome measure(s)

  • Change From Baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total Score at Week 26 — Baseline, Week 26

Trial sites (132)

FacilityCityRegionStatus
Research Site Orange California
Research Site Fort Collins Colorado
Research Site Washington D.C. District of Columbia
Research Site Bradenton Florida
Research Site Maitland Florida
Research Site Tampa Florida
Research Site Augusta Georgia
Research Site Gainesville Georgia
Research Site Savannah Georgia
Research Site Springfield Illinois
Research Site Kansas City Kansas
Research Site Lexington Kentucky
Research Site Detroit Michigan
Research Site East Lansing Michigan
Research Site Las Vegas Nevada
Research Site Patchogue New York
Research Site Rochester New York
Research Site Syracuse New York
Research Site Chapel Hill North Carolina
Research Site North Charleston South Carolina
Research Site Houston Texas
Research Site Richmond Virginia
Research Site Morgantown West Virginia
Research Site CABA Argentina
Research Site Ciudad de Buenos Aires Argentina
Research Site Ciudad de Buenos Aires Argentina
Research Site Ciudad de Buenos Aires Argentina
Research Site Rosario Argentina
Research Site Innsbruck Austria
Research Site Wels Austria
Research Site Barretos Brazil
Research Site Joinville Brazil
Research Site Porto Alegre Brazil
Research Site Ribeirão Preto Brazil
Research Site Salvador Brazil
Research Site São José do Rio Preto Brazil
Research Site São Paulo Brazil
Research Site Edmonton Alberta
Research Site Toronto Ontario
Research Site Québec Quebec

+ 92 more sites — see the full list on the official registry below.

More Alexion Pharmaceuticals, Inc. trials in the UK

Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism Active, not recruiting
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) Active, not recruiting
Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN) Recruiting
Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP Active, not recruiting
Safety, PK/PD, and Immunogenicity Study of SC ALXN2030 in Healthy Participants Active, not recruiting

Other trials for the same condition

Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis Active, not recruiting
A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis Recruiting
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis Active, not recruiting
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG) Recruiting
A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05556096 on ClinicalTrials.gov ↗ ← All trials in the UK